Carteolol HCl Ophthalmic Solution Rx
Generic Name and Formulations:
Carteolol HCl 1%; contains benzalkonium chloride.
Indications for Carteolol HCl Ophthalmic Solution:
Open-angle glaucoma. Ocular hypertension.
1 drop in affected eye(s) twice daily. Concomitant pilocarpine and other miotics, and/or epinephrine or dipivefrin, and/or systemically administered carbonic anhydrase inhibitors may be used if needed.
Sinus bradycardia. Greater than 1st-degree AV block. Cardiogenic shock. Overt cardiac failure. Asthma. Severe COPD.
History of cardiac failure or heart block. Discontinue at 1st sign of cardiac failure. Pulmonary impairment. Diabetes (esp. labile). May mask hypoglycemia and hyperthyroidism. May potentiate muscle weakness. Discontinue before general anesthesia. Avoid abrupt cessation. Pregnancy (Cat.C). Nursing mothers.
May potentiate or be potentiated by systemic β-blockers. May potentiate reserpine, hypoglycemics. May antagonize adrenergic psychotropics.
Ocular: transient eye irritation, burning, tearing, conjunctival hyperemia and edema, blurred/cloudy vision, photophobia, decreased night vision, ptosis; rarely: blepharoconjunctivitis, abnormal corneal staining, corneal sensitivity. Systemic: cardiac arrhythmia, heart palpitation, dyspnea, asthenia, headache, dizziness, insomnia, sinusitis, taste perversion.
Formerly known under the brand name Ocupress.
Soln—5mL, 10mL, 15mL
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Differences in Efficacy and Tolerability of ADHD Medications Across Age Groups
- Associations Between Hypovitaminosis D and Poorer Outcomes in Schizophrenia
- Oxycontin's Maker Now Selling Drug to Curb Opioid Addiction
- Comorbid Narcolepsy and Schizophrenia in Adolescents
- Ketamine in Electroconvulsive Therapy Accelerates Antidepressive Effects
- Incorporating Guidelines Into Clinical Practice: An Interview With Gary L. LeRoy, MD
- Disaster Preparedness 101: Physician Resources for Patients
- Adverse Events Caused by Once-Monthly Aripiprazole Are Time Limited
- Quetiapine Exposure Does Not Appear to Increase Risk for Infant Malformations
- Selective Serotonin Reuptake Inhibitors May Increase Risk for Suboptimal Fetal Growth